FDA Approves IND Application for Immuron’s IMM-529 to Treat C. difficile Infection
Immuron Limited has received FDA approval for its IND application for IMM-529, enabling a Phase 2 clinical trial for treating Clostridioides difficile infection (CDI). The drug, which uses antibodies from hyperimmune bovine colostrum, aims to prevent and treat CDI, including recurrent cases. The trial is set to begin in the first half of 2026. This announcement was made on November 05, 2025, and is for informational purposes only, not to be considered as financial or legal advice.